Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an update.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 73,684,211 new fully paid ordinary shares, to be issued on 1 May 2026. The move expands the company’s quoted share base and may support future capital needs, potentially enhancing liquidity for investors and providing additional financial flexibility for its development and commercial objectives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code PAR. The company operates in the life sciences sector, focusing on the development and commercialisation of pharmaceutical products for medical markets.
Average Trading Volume: 1,317,472
Technical Sentiment Signal: Sell
Current Market Cap: A$79.06M
Learn more about PAR stock on TipRanks’ Stock Analysis page.